Shattuck Labs Inc
Research Shattuck Labs Inc (STTK) on Bullrun: market cap USD 811.85M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSTTK
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 811.85M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 14.77M
- Free cash flow-USD 13.42M
Valuation Snapshot
latest market cap is USD 811.85M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.00M | -USD 48.81M | -USD 39.95M | n/a | -0.7 | USD 54.19M | USD 2.42M | USD 82.39M |
| FY2024 | USD 5.72M | -USD 75.41M | -USD 60.57M | n/a | -1.49 | USD 57.39M | USD 3.41M | USD 79.63M |
| FY2023 | USD 1.66M | -USD 87.30M | -USD 81.64M | n/a | -2.05 | USD 125.63M | USD 4.20M | USD 144.71M |
| FY2022 | USD 652.00K | -USD 101.95M | -USD 106.11M | n/a | -2.41 | USD 47.38M | USD 4.57M | USD 176.16M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 811.85M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 230.97M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 57.73M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 336.08M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 97.50M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 360.30M | n/a | n/a | n/a |
About Shattuck Labs Inc
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Shattuck Labs Inc's market cap?
Shattuck Labs Inc's market capitalization is USD 811.85M.
What does Shattuck Labs Inc do?
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.